SCHEMBL12350254

SCHEMBL12350254

O=S(=O)(O)c1ccccc1-c1ccc2[nH]c(C3CC3c3cccc(C(F)(F)F)c3)nc2c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 6/20 0.37
▸ LMNA P02545 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HTR2A P28223 2/20 0.35
▸ HTR2C P28335 2/20 0.35
▸ HTR2B P41595 2/20 0.35
▸ NPY5R Q15761 1/20 0.35
▸ LPAR2 Q9HBW0 1/20 0.35
▸ F10 P00742 1/20 0.34
▸ PDPK1 O15530 1/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ PRCP P42785 1/20 0.32
▸ HCRTR1 O43613 1/20 0.32
▸ HCRTR2 O43614 1/20 0.32
▸ KDM1A O60341 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1799004 0.91 TRPV1 (0.47) TRPV1LMNASMN1; SMN2HTR2AHTR2C
SCHEMBL1800454 0.85 TRPV1 (0.51) TRPV1LMNASMN1; SMN2HTR2AHTR2C
SCHEMBL1798504 0.84 TRPV1 (0.47) TRPV1LMNASMN1; SMN2LPAR2HCRTR1
SCHEMBL1797840 0.83 TRPV1 (0.49) TRPV1KDM1A
SCHEMBL1796254 0.83 TRPV1 (0.40) TRPV1LMNASMN1; SMN2NPY5RLPAR2
SCHEMBL1796625 0.82 TRPV1 (0.47) TRPV1LMNASMN1; SMN2HTR2AHTR2C
SCHEMBL1797750 0.82 TRPV1 (0.52) TRPV1NPY5RF10ROCK2
SCHEMBL1798709 0.82 TRPV1 (0.52) TRPV1NPY5RF10ROCK2
SCHEMBL1797782 0.82 POLB (0.45) TRPV1NPY5RROCK2POLB
SCHEMBL1800621 0.82 TRPV1 (0.52) TRPV1NPY5RF10ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190344-A1 BENZIMIDAZOLE MODULATORS OF VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2011-08-04 — — US disclosed
US-20110190344-A1 BENZIMIDAZOLE MODULATORS OF VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2011-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190344-A1 BENZIMIDAZOLE MODULATORS OF VR1 VRK1, VRK2, VIL1 TRPV1 29/4885LMNA 4066/4885SMN1; SMN2 4562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback